Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Anim Sci J ; 91(1): e13475, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33078490

RESUMEN

Growth performance of pigs has been associated with healthy gut microbiota. To improve production, pigs are usually treated with antimicrobials. Nonetheless, while antimicrobials harm the gut-indigenous microbiota, probiotic supplementation seems to help keep it healthy. Here, using antimicrobials, we artificially induced dysbiosis in pigs and evaluated a possible preventive effect of probiotic supplementation. Three 6-week-old piglets were given a basal feed, and 3 more the feed supplemented with 2.0 × 106  CFU of Bacillus subtilis QST713/g of feed. After 14 days, antimicrobial enrofloxacin (5 mg/kg B.W.) was injected intramuscularly to all pigs on days 14-16. Feces were collected on days 14, 17, 19, 21, and 23. Total bacteria count was unaffected by enrofloxacin or QST713. However, Lactobacillus spp. and, in particular, Escherichia coli were affected by enrofloxacin, the latter not being observed in the feces on days 17 and 19. Interestingly, a reciprocal increase in E. coli was observed in control pigs on days 21 and 23, although in QST713-supplemented piglets, this increase was attenuated. While the gut microbiota composition did not return to initial levels in antimicrobial-administered piglets, it did in QST713-supplemented piglets. QST713 supplementation was likely crucial to keep the microbiota of piglets healthy.


Asunto(s)
Antibacterianos/efectos adversos , Bacillus subtilis , Suplementos Dietéticos , Disbiosis/prevención & control , Disbiosis/veterinaria , Enrofloxacina/efectos adversos , Probióticos/administración & dosificación , Enfermedades de los Porcinos/prevención & control , Animales , Antibacterianos/administración & dosificación , Disbiosis/inducido químicamente , Disbiosis/microbiología , Enrofloxacina/administración & dosificación , Heces/microbiología , Microbioma Gastrointestinal , Inyecciones Intramusculares , Porcinos , Enfermedades de los Porcinos/inducido químicamente , Enfermedades de los Porcinos/microbiología
2.
Sci Rep ; 10(1): 5583, 2020 03 27.
Artículo en Inglés | MEDLINE | ID: mdl-32221366

RESUMEN

Bio-logging devices can provide unique insights on the life of freely moving animals. However, implanting these devices often requires invasive surgery that causes stress and physiological side-effects. While certain medications in connection to surgeries have therapeutic capacity, others may have aversive effects. Here, we hypothesized that the commonly prescribed prophylactic treatment with enrofloxacin would increase the physiological recovery rate and reduce the presence of systemic inflammation following the intraperitoneal implantation of a heart rate bio-logger in rainbow trout (Oncorhynchus mykiss). To assess post-surgical recovery, heart rate was recorded for 21 days in trout with or without enrofloxacin treatment. Contrary to our hypothesis, treated trout exhibited a prolonged recovery time and elevated resting heart rates during the first week of post-surgical recovery compared to untreated trout. In addition, an upregulated mRNA expression of TNFα in treated trout indicate a possible inflammatory response 21 days post-surgery. Interestingly, the experience level of the surgeon was observed to have a long-lasting impact on heart rate. In conclusion, our study showed no favorable effects of enrofloxacin treatment. Our findings highlight the importance of adequate post-surgical recovery times and surgical training with regards to improving the welfare of experimental animals and reliability of research outcomes.


Asunto(s)
Profilaxis Antibiótica/veterinaria , Oncorhynchus mykiss/cirugía , Tecnología de Sensores Remotos/veterinaria , Animales , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Enrofloxacina/efectos adversos , Enrofloxacina/uso terapéutico , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Hidrocortisona/sangre , Inflamación/prevención & control , Inflamación/veterinaria , Masculino , Peritoneo/cirugía , ARN Mensajero/metabolismo , Tecnología de Sensores Remotos/efectos adversos , Tecnología de Sensores Remotos/instrumentación , Tecnología de Sensores Remotos/métodos
3.
Pol J Vet Sci ; 20(3): 567-572, 2017 Sep 26.
Artículo en Inglés | MEDLINE | ID: mdl-29166279

RESUMEN

The aim of the study was to analyse the influence of enrofloxacin and pradofloxacin administered orally for 14 days on the ECG in dogs. The ECG was performed before and after a 14 day period of quinolone administration. There was an increase in the QTc and the TpTe interval in the group treated with quinolones. QTc was prolonged by 24 ms (p=0.001). The TpTe interval was shortened, on average, by 6.55 ms (p=0.048). In the group treated with enrofloxacin, QTc was prolonged by 16.27 ms (p=0.006) and the TpTe interval was shortened by 9.64 ms (p=0.050), the TpTe/QT index was reduced by 0.034 (p=0.050) on average. In dogs treated with pradofloxacin, QTc was prolonged by 21.55 ms (p=0.012) on average. The results suggest that a prolonged administration of quinolones can increase the risk of arrhythmias. Furthermore, different generations of these drugs increase this risk to various degrees. The study proved that second generation quinolones, such as enrofloxacin, significantly change the phase of depolarization and repolarization of the ventricles, at the same time increasing the risk of ventricular arrythmia. Pradofloxacin does not change the TpTe and TpTe/QT values, so it is safer in use.


Asunto(s)
Electrocardiografía/veterinaria , Enrofloxacina/efectos adversos , Enrofloxacina/uso terapéutico , Fluoroquinolonas/efectos adversos , Fluoroquinolonas/uso terapéutico , Animales , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Perros , Esquema de Medicación , Electrocardiografía/efectos de los fármacos , Enrofloxacina/administración & dosificación , Femenino , Fluoroquinolonas/administración & dosificación , Masculino , Piodermia/tratamiento farmacológico , Piodermia/veterinaria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA